Study #2024-0206
Phase 1/2 study of TSN1611 in subjects with advanced solid tumors harboring KRAS G12D mutation
MD Anderson Study Status
Enrolling
Treatment Agent
TSN1611
Description
The study is a first-in-human (FIH), open-label, multi-center phase 1/2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant Neoplasm
Study phase:
Physician name:
Siqing Fu
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-844-935-4058
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.